F D C

F D C Net Margin

The Net Profit Margin of F D C (FDC.NS) as of Oct 25, 2026 is 12.66 %. In the previous year, Net Profit Margin was 15.71 % — a change of -19.44% (lower).

Net Margin

12.66 %

YoY

-19.44%

Last updated:

Net Profit Margin of F D C is 2025 12.66 % . Net Profit Margin of F D C was 2024 15.71 % . It decreases by -19.44% lower compared to the previous year.

F D C's net margin stands at 12.7%, down from 22.6% several years earlier.

The F D C Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
16.02 INR
Jan 1, 2019
15.57 INR
Jan 1, 2020
17.85 INR
Jan 1, 2021
22.60 INR
Jan 1, 2022
14.16 INR
Jan 1, 2023
10.88 INR
Jan 1, 2024
15.71 INR
Jan 1, 2025
12.66 INR
The F D C Net Margin history
YEARNet MarginYoY
12.66 %-19.44%
15.71 %+44.41%
10.88 %-23.20%
14.16 %-37.34%
22.60 %+26.66%
17.85 %+14.64%
15.57 %-2.83%
16.02 %-10.70%
17.94 %+8.20%
16.58 %-0.48%
16.66 %+4.13%
16.00 %+7,865.94%
0.20 %+6.40%
0.19 %-10.98%
0.21 %-10.11%
0.24 %+61.20%
0.15 %+14.63%
0.13 %-15.39%
0.15 %-24.28%
0.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

F D C Stock analysis

What does F D C do? FDC Ltd. generates revenue through the manufacturing and distribution of pharmaceutical generics, formulations, and active pharmaceutical ingredients (APIs). The company produces specialized products such as oral rehydration salts (ORS) and functional foods and beverages, targeting therapeutic segments including anti-infectives, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. Its branded products like Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm are sold to healthcare providers and consumers across these segments. The company's APIs, including Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate, and Timolol Maleate, support its formulation business. FDC Ltd. distributes its products through its manufacturing plants, serving both domestic and international markets with a focus on cost-effective generic medicines and specialized formulations. FDC Ltd. targets healthcare providers, hospitals, and retail pharmacies as key buyers of its branded pharmaceuticals and functional products. The company's product portfolio spans multiple therapeutic areas, with brands like Zifi for respiratory conditions and Electral for rehydration, catering to diverse consumer needs in the Indian pharmaceutical market. F D C is one of the most popular companies on Eulerpool.

Frequently Asked Questions about F D C stock

Net Profit Margin of F D C is 12.66 % in 2025.

Net Profit Margin of F D C changed from 15.71 % to 12.66 %, representing a -19.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin F D C since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's F D C with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — F D C

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — F D C